All In Biotech

Drug Trial Radar · NCT05866562

Dupilumab in the Treatment of Pediatric Alopecia Areata

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Jul 11, 2024

Primary completion

Mar 31, 2029

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
May 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48. All subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥200 and/or have personal and/or familial history of atopy. Study participation will be up to 124 weeks, consisting of: a screening period of up to 4 weeks; a 48-week placebo-controlled period; a 48-week open-label extension period; followed by a 24-week follow-up period.

Conditions

  • Alopecia Areata

Interventions

  • DupilumabDrug

    Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;

  • PlaceboDrug

    Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Severity of Alopecia Tool (SALT) scoreTime frame: Baseline and Week 48

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of California San Diego

    San Diego, California · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.